Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCCLillian L. Siu, Jérôme Fayette, Amaury Daste et al.|JAMA Oncology|2018Cited by 315
The HIT-network for children and adolescents with CNS tumors facilitates improvements of diagnostic assessments, multimodal treatments, individual counselling, and research in Germany, Austria, and SwitzerlandStefan Rutkowski, Johannes Gojo, Michael Frühwald C et al.|Unknown|2025Cited by 1